IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.
Insulin-like growth factor 2 (IGF2) overexpression is an important molecular marker of adrenocortical carcinoma (ACC), which is a rare but devastating endocrine cancer. It is not clear whether IGF2 overexpression modifies the biology and growth of this cancer, thus more studies are required before I...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d93b7d6056db476b9f50e1676676fe75 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d93b7d6056db476b9f50e1676676fe75 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d93b7d6056db476b9f50e1676676fe752021-11-25T06:06:08ZIGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.1932-620310.1371/journal.pone.0103744https://doaj.org/article/d93b7d6056db476b9f50e1676676fe752014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25089899/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Insulin-like growth factor 2 (IGF2) overexpression is an important molecular marker of adrenocortical carcinoma (ACC), which is a rare but devastating endocrine cancer. It is not clear whether IGF2 overexpression modifies the biology and growth of this cancer, thus more studies are required before IGF2 can be considered as a major therapeutic target. We compared the phenotypical, clinical, biological, and molecular characteristics of ACC with or without the overexpression of IGF2, to address these issues. We also carried out a similar analysis in an ACC cell line (H295R) in which IGF2 expression was knocked down with si- or shRNA. We found no significant differences in the clinical, biological and molecular (transcriptomic) traits between IGF2-high and IGF2-low ACC. The absence of IGF2 overexpression had little influence on the activation of tyrosine kinase pathways both in tumors and in H295 cells that express low levels of IGF2. In IGF2-low tumors, other growth factors (FGF9, PDGFA) are more expressed than in IGF2-high tumors, suggesting that they play a compensatory role in tumor progression. In addition, IGF2 knock-down in H295R cells substantially impaired growth (>50% inhibition), blocked cells in G1 phase, and promoted apoptosis (>2-fold). Finally, analysis of the 11p15 locus showed a paternal uniparental disomy in both IGF2-high and IGF2-low tumors, but low IGF2 expression could be explained in most IGF2-low ACC by an additional epigenetic modification at the 11p15 locus. Altogether, these observations confirm the active role of IGF2 in adrenocortical tumor growth, but also suggest that other growth promoting pathways may be involved in a subset of ACC with low IGF2 expression, which creates opportunities for the use of other targeted therapies.Marine Guillaud-BatailleBruno RagazzonAurélien de ReynièsClaire ChevalierIsabelle FrancillardOlivia BarreauVirginie SteunouJohann GuillemotFrédérique TissierMarthe Rizk-RabinFernande René-CorailAbir Al GhuzlanGuillaume AssiéXavier BertagnaEric BaudinYves Le BoucJérôme BertheratEric ClauserPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 8, p e103744 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Marine Guillaud-Bataille Bruno Ragazzon Aurélien de Reyniès Claire Chevalier Isabelle Francillard Olivia Barreau Virginie Steunou Johann Guillemot Frédérique Tissier Marthe Rizk-Rabin Fernande René-Corail Abir Al Ghuzlan Guillaume Assié Xavier Bertagna Eric Baudin Yves Le Bouc Jérôme Bertherat Eric Clauser IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| description |
Insulin-like growth factor 2 (IGF2) overexpression is an important molecular marker of adrenocortical carcinoma (ACC), which is a rare but devastating endocrine cancer. It is not clear whether IGF2 overexpression modifies the biology and growth of this cancer, thus more studies are required before IGF2 can be considered as a major therapeutic target. We compared the phenotypical, clinical, biological, and molecular characteristics of ACC with or without the overexpression of IGF2, to address these issues. We also carried out a similar analysis in an ACC cell line (H295R) in which IGF2 expression was knocked down with si- or shRNA. We found no significant differences in the clinical, biological and molecular (transcriptomic) traits between IGF2-high and IGF2-low ACC. The absence of IGF2 overexpression had little influence on the activation of tyrosine kinase pathways both in tumors and in H295 cells that express low levels of IGF2. In IGF2-low tumors, other growth factors (FGF9, PDGFA) are more expressed than in IGF2-high tumors, suggesting that they play a compensatory role in tumor progression. In addition, IGF2 knock-down in H295R cells substantially impaired growth (>50% inhibition), blocked cells in G1 phase, and promoted apoptosis (>2-fold). Finally, analysis of the 11p15 locus showed a paternal uniparental disomy in both IGF2-high and IGF2-low tumors, but low IGF2 expression could be explained in most IGF2-low ACC by an additional epigenetic modification at the 11p15 locus. Altogether, these observations confirm the active role of IGF2 in adrenocortical tumor growth, but also suggest that other growth promoting pathways may be involved in a subset of ACC with low IGF2 expression, which creates opportunities for the use of other targeted therapies. |
| format |
article |
| author |
Marine Guillaud-Bataille Bruno Ragazzon Aurélien de Reyniès Claire Chevalier Isabelle Francillard Olivia Barreau Virginie Steunou Johann Guillemot Frédérique Tissier Marthe Rizk-Rabin Fernande René-Corail Abir Al Ghuzlan Guillaume Assié Xavier Bertagna Eric Baudin Yves Le Bouc Jérôme Bertherat Eric Clauser |
| author_facet |
Marine Guillaud-Bataille Bruno Ragazzon Aurélien de Reyniès Claire Chevalier Isabelle Francillard Olivia Barreau Virginie Steunou Johann Guillemot Frédérique Tissier Marthe Rizk-Rabin Fernande René-Corail Abir Al Ghuzlan Guillaume Assié Xavier Bertagna Eric Baudin Yves Le Bouc Jérôme Bertherat Eric Clauser |
| author_sort |
Marine Guillaud-Bataille |
| title |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| title_short |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| title_full |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| title_fullStr |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| title_full_unstemmed |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| title_sort |
igf2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/d93b7d6056db476b9f50e1676676fe75 |
| work_keys_str_mv |
AT marineguillaudbataille igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT brunoragazzon igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT aureliendereynies igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT clairechevalier igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT isabellefrancillard igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT oliviabarreau igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT virginiesteunou igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT johannguillemot igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT frederiquetissier igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT martherizkrabin igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT fernanderenecorail igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT abiralghuzlan igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT guillaumeassie igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT xavierbertagna igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT ericbaudin igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT yveslebouc igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT jeromebertherat igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma AT ericclauser igf2promotesgrowthofadrenocorticalcarcinomacellsbutitsoverexpressiondoesnotmodifyphenotypicandmolecularfeaturesofadrenocorticalcarcinoma |
| _version_ |
1718414193926864896 |